A Phase 2 interventional study of Aleniglipron and Placebo in Obese, Obesity and Obesity Type 2 Diabetes Mellitus, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 58 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug aleniglipron administered orally
Drug: Aleniglipron
Drug placebo administered orally
Drug: Placebo
Drug aleniglipron administered orally
Drug placebo administered orally
Incidence, severity and relationship of AEs/SAEs
Time frame: Baseline to week 31
Assessment of vital signs
Number of Participants with Clinically Significant Change from Baseline in Vital Signs: including Systolic and Diastolic Blood Pressure, Heart Rate, and temperature.
Time frame: Baseline to week 31
Assessment of laboratory measures
Number of Participants with Abnormal Laboratory Parameters: including hematology, serum chemistry, coagulation
Time frame: Baseline to week 31
Assessment of Electrocardiograms (ECG)
Number of Participants with Clinically Significant Change from Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to: ventricular heart rate, PR interval, QRS duration, QT interval, and QTcF
Time frame: Baseline to week 31
Absolute change in body weight from Baseline
Time frame: Baseline to week 31
Percent change in body weight from Baseline
Time frame: Baseline to week 31
Change in HbA1c from Baseline
Time frame: Baseline to week 30
Change in fasting plasma glucose from Baseline
Time frame: Baseline to week 31
PK parameters including but not limited to AUC
Time frame: Baseline to week 30
PK parameters including but not limited to Cmax
Time frame: Baseline to week 30
PK parameters including but not limited to Tmax
Time frame: Baseline to week 30
PK parameters including but not limited to Ctrough
Time frame: Baseline to week 30
Plan to share: Yes — De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request
Supporting information: Study protocol
Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product has been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Gasherbrum Bio, Inc. does not grant external requests for individual de-identified patient data for the following purposes: Re-evaluating safety and efficacy end points already addressed in the product labelling, Assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Sep 2026, 9 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics →